This is in line with findings by others who found CD8+ TIL infiltration to remain stable or even increase after neoadjuvant platinum-based chemotherapy in ovarian cancer [58,59,60,61], implying that platinum-based chemotherapy may augment a pre-existing immune response. The gene discussed is CD8A; the disease is ovarian cancer.